Multiply Labs Raises $75M to Automate Complex Drug Manufacturing

Startups15 days ago

AstraZeneca and Legend Biotech are using autonomous robotics from Multiply Labs to produce mRNA treatments and other complex gene therapies. The robotics startup secured $75 million in a Series B financing round to scale this technology, with the investment led by NantWorks, the holding company of billionaire Patrick Soon-Shiong. Other participants in the round include Lux Capital, Founders Fund, and AstraZeneca, which is both an investor and a customer.

The funding targets a bottleneck in the pharmaceutical industry where AI has accelerated drug discovery but physical production remains manual. Hand-led manufacturing is slow and can cost more than $1 million per dose for certain therapies due to labor intensity and contamination risks. Multiply Labs, a graduate of the Y Combinator S16 cohort, builds robots to shift these processes to automated systems.

Mapped to your portfolio

Possible scenarios

40%Automation Platform Scales+0.1%
30%Gradual Workflow Adoption+0.0%
20%Validation Delays Emerge-0.0%

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.

Looking for more context or analysis?

Tilt chat provides reliable, tailored insights, alerts, and automations.

Multiply Labs Raises $75M to Automate Complex Drug Manufacturing

In this story

Multiply Labs AstraZeneca Legend Biotech NantWorks Patrick Soon-Shiong Lux Capital Founders Fund

Portfolio

SPY
State Street SPDR S&P 500 ETF Trust
100%

Portfolio

SPY
State Street SPDR S&P 500 ETF Trust
100%

Mapped to your portfolio

Possible scenarios

40%Automation Platform Scales+0.1%
30%Gradual Workflow Adoption+0.0%
20%Validation Delays Emerge-0.0%

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.